General Oncology, Inc.
Clinical-stage biopharmaceutical company developing first-in-class therapies for metastatic and proliferative diseases. Focus areas include repurposed combination chemotherapy regimens that impair tumor DNA repair, discovery of ultra-high potency small molecules that cross-link DNA, and clinical development of these candidates through IND-enabling studies and early-phase trials. The company sponsors investigator-collaborative trials and presents clinical data at scientific conferences.
Industries
N/A
Nr. of Employees
small (1-50)
General Oncology, Inc.
57 Chapel Street, Third Floor, Newton, MA 02458
Patents
Products
Repurposed combination regimen for BRCA-mutated cancers (clinical-stage)
A clinical-stage repurposed multi-drug regimen combining DNA cross-linking and redox-modulating agents with autologous stem cell rescue to impair tumor DNA repair and sensitize cancer cells to cytotoxic therapy for BRCA/PALB2-mutated pancreatic and breast cancers.
Preclinical ultra-high potency DNA cross-linking small-molecule candidates
Discovery-stage portfolio of novel small molecules believed to irreversibly cross-link DNA, being advanced toward IND-enabling studies for indications including solid tumors and hematologic malignancies.
Repurposed combination regimen for BRCA-mutated cancers (clinical-stage)
A clinical-stage repurposed multi-drug regimen combining DNA cross-linking and redox-modulating agents with autologous stem cell rescue to impair tumor DNA repair and sensitize cancer cells to cytotoxic therapy for BRCA/PALB2-mutated pancreatic and breast cancers.
Preclinical ultra-high potency DNA cross-linking small-molecule candidates
Discovery-stage portfolio of novel small molecules believed to irreversibly cross-link DNA, being advanced toward IND-enabling studies for indications including solid tumors and hematologic malignancies.
Services
Sponsorship and operational oversight of investigator-collaborative Phase 1 trials evaluating combination regimens in BRCA/PALB2-mutated cancers, with planned expansion to broader populations.
Sponsorship and operational oversight of investigator-collaborative Phase 1 trials evaluating combination regimens in BRCA/PALB2-mutated cancers, with planned expansion to broader populations.
Expertise Areas
- Clinical trial management (Phase 1–2)
- Oncology drug development
- Combination chemotherapy repurposing
- DNA cross-linking small-molecule discovery
Key Technologies
- DNA cross-linking agents
- Redox modulation to impair DNA repair
- Autologous stem cell infusion
- Repurposed combination chemotherapy regimens
News & Updates
Poster presentation of interim Phase 1 data demonstrating manageable safety and signals of efficacy for a redox-modulating, DNA cross-linking combination regimen in BRCA-mutated pancreatic and breast cancer.
Formalization of a Scientific Advisory Board composed of oncology clinical and research leaders to advise on target identification and clinical development strategies.
Company senior management participated in multiple industry conferences and partnering events in 2025.
Appointment of an experienced biotech finance executive to support corporate development and capital strategy.
Podcast interview discussing the investigational combination therapy approach of using repurposed chemotherapies in a novel regimen to address drug resistance.
Podcast interview featuring the company's CFO discussing fundraising and company strategy.
Poster presentation of interim Phase 1 data demonstrating manageable safety and signals of efficacy for a redox-modulating, DNA cross-linking combination regimen in BRCA-mutated pancreatic and breast cancer.
Formalization of a Scientific Advisory Board composed of oncology clinical and research leaders to advise on target identification and clinical development strategies.
Company senior management participated in multiple industry conferences and partnering events in 2025.
Appointment of an experienced biotech finance executive to support corporate development and capital strategy.
Podcast interview discussing the investigational combination therapy approach of using repurposed chemotherapies in a novel regimen to address drug resistance.
Podcast interview featuring the company's CFO discussing fundraising and company strategy.